Company Announcements
Change of Adviser
Related Companies
By LSE RNS
25 January 2018
Venn Life Sciences Holdings plc
("Venn" or the "Company" or the "Group")
Appointment of Nominated Adviser and Broker
Venn Life Sciences Holdings plc, the AIM drug development services organisation, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.
Enquiries:
|
Venn Life Sciences Holdings plc |
www.vennlifesciences.com |
|
Allan Wood, Non-Executive Chairman |
Tel: +44 (0)7785 325 898 |
|
Tony Richardson, Chief Executive Officer |
Tel: +353 1 5499341 |
|
|
|
|
Cenkos (Nominated Adviser and Broker) |
Tel: +44(0)20 7397 8900 |
|
Mark Connelly/Steve Cox (Corporate Finance) |
|
|
|
|
|
Davy (ESM Adviser and Broker) |
Tel: +353 1 679 6363 |
|
Fergal Meegan / Matthew de Vere White (Corporate Finance) |
|
|
|
|
|
Hybridan LLP ( Joint Broker) |
Tel: +44 (0)20 3764 2341 |
|
Claire Louise Noyce |
|
About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences is available on their website - www.vennlifesciences.com
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN